- |||||||||| Observational data, Retrospective data, Journal, HEOR, Real-world evidence, Real-world: Real-world evidence evaluation on consumer experience and prescription journey of diclofenac gel in Sweden. (Pubmed Central) - Aug 23, 2024
This real-world study provides important insights into the prescription patterns of diclofenac gel and the consumer experience with OTC VGD in Sweden. Patients rarely switched to other topical nonsteroidal anti-inflammatory drugs, and VGD consumers reported pain relief and improved HRQoL compared to baseline - resulting in treatment satisfaction.
- |||||||||| Trial completion date, Trial primary completion date: DITCH: Diclofenac Gel in the Treatment of Cervicogenic Headache (clinicaltrials.gov) - Aug 2, 2024
P3, N=50, Recruiting,
Patients rarely switched to other topical nonsteroidal anti-inflammatory drugs, and VGD consumers reported pain relief and improved HRQoL compared to baseline - resulting in treatment satisfaction. Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
- |||||||||| Comparative Sensory Analysis of Novel Topical Diclofenac Hydrogel with Conventional Diclofenac Gel (Exhibit Hall) - Jul 31, 2024 - Abstract #PAINWeek2024PAINWeek_158;
Specifically, the questions with the greatest separation from vehicle at week 6 involved pain when turning and squeezing objects, stiffness upon wakening, difficulty turning doorknobs and faucets, and difficulty getting dressed, all of which are important components of hand functionality in daily living. Participants rated the hydrogel significantly higher for ease of application (91% vs. 85%), quickness to apply (88% vs. 82%), cooling sensation (74% vs.
- |||||||||| Journal: Alternatives to Conventional Topical Dosage Forms for Targeted Skin Penetration of Diclofenac Sodium. (Pubmed Central) - Jul 13, 2024
Rheological characterisation of the prototypes revealed similar profiles of cream-gel and emulgel benchmark, whereas gel-in-oil emulsion demonstrated flow characteristics suitable for massaging product into the skin. This study underlined the potential of cream-gel and gel-in-oil emulsions for adjusting active penetration into the skin, broadening the range of choices available to topical formulation scientists.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma, Nucynta (tapentadol) / Collegium Pharma, Grunenthal
Perioperative Pain Medicine in Multi-specialty Anesthesiology Practice for Patients With Long COVID Pain Syndrome (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_1229;
What are the indications and available preparations of buprenorphine with various route of delivery systems?10.A PACU nurse mentioned a friend had positive feedback with low dose naltrexone (LDN) as chronic pain medicine...How do opioid antagonist contribute to analgesia? Are there any scientific basis and evidence-based medicine to use LDN for long COVID pain syndrome?
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma, Nucynta (tapentadol) / Collegium Pharma, Grunenthal
Perioperative Pain Medicine in Multi-specialty Anesthesiology Practice for Patients With Long COVID Pain Syndrome (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_922;
What are the indications and available preparations of buprenorphine with various route of delivery systems?10.A PACU nurse mentioned a friend had positive feedback with low dose naltrexone (LDN) as chronic pain medicine...How do opioid antagonist contribute to analgesia? Are there any scientific basis and evidence-based medicine to use LDN for long COVID pain syndrome?
- |||||||||| Journal: Topical Diclofenac Versus Oral Ibuprofen Versus Diclofenac (Pubmed Central) - May 22, 2024
Among patients with nontraumatic, nonradicular acute musculoskeletal low back pain discharged from an ED, topical diclofenac was probably less efficacious than oral ibuprofen. It demonstrated no additive benefit when coadministered with oral ibuprofen.
- |||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Klisyri (tirbanibulin ointment) / Hanmi, Almirall, Athenex, PharmaEssentia
Review, Journal: Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review. (Pubmed Central) - May 5, 2024
Photodynamic therapy (PDT) with either aminolevulinic acid (ALA) or methylaminolevulinate (MAL), as well as topical treatments such as 5-fluorouracil (5-FU), diclofenac gel, piroxicam, imiquimod, and ingenol mebutate, have all shown higher efficacy than vehicle treatments...Tirbanibulin, a new topical agent approved for use in 2020, boasts a favorable safety profile in comparison with imiquimod, 5-FU, and diclofenac...Moving forward, an increasing number of studies push for standardization of outcome measures to better predict risk of future cSCC and use of more effective measures of cost to better guide patients. Here, we present an updated and comprehensive narrative review both confirming the efficacy of previously mentioned therapies as well as highlighting new approaches to PDT and discussing the use of lasers and novel topical treatments for treatment of AK.
- |||||||||| Trial completion date, Trial primary completion date: DITCH: Diclofenac Gel in the Treatment of Cervicogenic Headache (clinicaltrials.gov) - Feb 21, 2024
P3, N=50, Recruiting,
All four different IVRT apparatuses were compared with each other and with the data found in the literature. Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: Jan 2025 --> Jun 2025
- |||||||||| eflornithine topical / Generic mfg.
Enrollment closed, Trial primary completion date: Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer (clinicaltrials.gov) - Dec 20, 2023
P2, N=138, Active, not recruiting,
LIPUS phonophoresis with diclofenac is more effective to ameliorate inflammation and pain compared to diclofenac or LIPUS alone, and the mechanism involves the decrease of M1 macrophages. Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2023 --> Nov 2024
- |||||||||| Insidious Onset of Xiphodynia with an Idiopathic Origin - A Case Report () - Nov 16, 2023 - Abstract #AAPMR2023AAPMR_920;
Patients with insidious onset of xiphisternal joint pain will have xiphodynia in the absence of other serious causes related to trauma, cardiopulmonary, or gastrointestinal etiology. The treatment of xiphodynia is based on symptom presentation with conservative management as the first-line therapy.
- |||||||||| A Case of Bilateral Protrusio Acetabuli () - Nov 16, 2023 - Abstract #AAPMR2023AAPMR_576;
This case demonstrates a unique presentation of bilateral protrusio acetabulli. Early diagnosis and prompt intervention can help minimize the risk of long-term complications.
- |||||||||| Retrospective data, Journal: The Impact of Non-opioid Analgesic Usage on Total Opioid Load During Traumatic Brain Injury Rehabilitation: A Retrospective Study. (Pubmed Central) - Nov 13, 2023
This study aimed to determine the association between non-opioid analgesic use and total opioid load, as measured using morphine milligram equivalents (MMEs), during inpatient rehabilitation for traumatic brain injury...Non-opioid medications that were reviewed in the study included acetaminophen, amitriptyline, baclofen, diclofenac, gabapentin, ibuprofen, lidocaine, methocarbamol, nortriptyline, and pregabalin...Results also showed that the mere presence of methocarbamol (regardless of daily or total dosage) had a significant effect on the ?MME. Conclusions Based on these findings, physicians may want to consider prescribing acetaminophen, gabapentin, or methocarbamol for patients admitted for inpatient rehabilitation following traumatic brain injury who require high amounts of opioids.
- |||||||||| Enrollment open: DITCH: Diclofenac Gel in the Treatment of Cervicogenic Headache (clinicaltrials.gov) - Oct 27, 2023
P3, N=50, Recruiting,
Within the limitations of the study, the results of our study concluded that novel herbal trio gel containing Linum usitatissimum extract, sorbitol, and carboxymethyl cellulose could be an efficient economic primeval substitute that is non-toxic, natural, and structured for clinical application. Not yet recruiting --> Recruiting
- |||||||||| Journal: Exploring the Drug-Loading and Release Ability of FucoPol Hydrogel Membranes. (Pubmed Central) - Oct 14, 2023
Moreover, for all API-loaded membranes, the release mechanism followed Fickian diffusion, with the release rate being essentially governed by the diffusion process. These findings, together with their previously shown biological properties, support the suitability of the developed FucoPol HMs to be used as platforms for the topical delivery of drugs.
- |||||||||| Post-hoc Analysis of Individual Questions from the Australian/Canadian Osteoarthritis Hand Index from a Randomized, Double-blind, Placebo-controlled Trial of Patients with Hand OA (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3306;
These endpoints may be more meaningful to patients than the subscale scores of pain, stiffness and physical function, and may provide healthcare providers better ways to communicate the benefit of using DSG to treat the symptoms of hand OA. Mean scores for individual AUSCAN questions (0-100 scale) K. Nicholson: Haleon, 3; E. Sanchez: Haleon, 3; W. Wright: Haleon, 2; J. Block: Haleon, 2; R. Petruschke: Haleon, 3.
- |||||||||| Peri-operative Pain Medicine In Multi-specialty Anesthesiology Practice For Patient With Long Covid Pain Syndrome (South: Hall D-7) - Jul 20, 2023 - Abstract #ASA2023ASA_2628;
Patient was on duloxetine daily and used muscle relaxant only as needed to relieve muscle tightness, spasms, diffuse body, joints, neck, and back pain.4.Patient reported inadequate pain control despite various IV opioids in PACU and had to stay overnight for observation and treatment...What are the options of oral pain medicine for acute postoperative pain in addition to worsening chronic diffuse body and joints pain?Patient failed previous tramadol, acetaminophen with codeine due to nausea and constipation with marginal pain relief...Perioperative patient care needs to minimize escalating opioids doses and minimize duration of opioid therapy for acute postoperative pain. It is crucial to advise patient compliance with COVID protective measures with goals to improve clinical postoperative outcomes and reduce overall healthcare cost.
- |||||||||| Peri-operative Pain Medicine In Multi-specialty Anesthesiology Practice For Patient With Long Covid Pain Syndrome (South: Hall D-7) - Jul 20, 2023 - Abstract #ASA2023ASA_64;
Patient was on duloxetine daily and used muscle relaxant only as needed to relieve muscle tightness, spasms, diffuse body, joints, neck, and back pain.4.Patient reported inadequate pain control despite various IV opioids in PACU and had to stay overnight for observation and treatment...What are the options of oral pain medicine for acute postoperative pain in addition to worsening chronic diffuse body and joints pain?Patient failed previous tramadol, acetaminophen with codeine due to nausea and constipation with marginal pain relief...Perioperative patient care needs to minimize escalating opioids doses and minimize duration of opioid therapy for acute postoperative pain. It is crucial to advise patient compliance with COVID protective measures with goals to improve clinical postoperative outcomes and reduce overall healthcare cost.
- |||||||||| Enrollment closed: DARE-PDM1: A Study of Diclofenac Gel in Women With Primary Dysmenorrhea (clinicaltrials.gov) - Jul 20, 2023
P1, N=36, Active, not recruiting,
It is crucial to advise patient compliance with COVID protective measures with goals to improve clinical postoperative outcomes and reduce overall healthcare cost. Not yet recruiting --> Active, not recruiting
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: KOHDIAK: 5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis (clinicaltrials.gov) - Mar 1, 2023
P3, N=631, Completed,
This trial establishes topical diclofenac as the new standard of care to prevent capecitabine associated HFS. Recruiting --> Completed | Trial completion date: Sep 2023 --> Jan 2023 | Trial primary completion date: Sep 2023 --> Jan 2023
- |||||||||| diclofenac sodium topical / Generic mfg.
Preclinical, Journal: Research of diclofenac sodium-loaded gelatin scaffold with anti-inflammatory activity for promoting in vivo cartilage regeneration (Pubmed Central) - Jan 29, 2023
In vivo experiments showed that the samples in the experimental group had porcelain white cartilage like morphology, histologic staining showed obvious cartilage lacuna structure and cartilage specific extracellular matrix, the contents of GAG and collagen type Ⅱ were significantly higher than those in the control group, and the protein and mRNA expressions of CD3 and CD68 were significantly lower than those in the control group, with significant differences (P<0.05). The diclofenac sodium-loaded gelatin scaffold presents suitable pore size, porosity, and cytocompatibility, as well as exhibited satisfactory anti-inflammatory ability, providing a reliable scheme for alleviating the inflammatory reaction of regenerated cartilage tissue after in vivo implantation and promoting cartilage regeneration in vivo.
- |||||||||| Trial initiation date: DITCH: Diclofenac Gel in the Treatment of Cervicogenic Headache (clinicaltrials.gov) - Jan 27, 2023
P3, N=50, Not yet recruiting,
The diclofenac sodium-loaded gelatin scaffold presents suitable pore size, porosity, and cytocompatibility, as well as exhibited satisfactory anti-inflammatory ability, providing a reliable scheme for alleviating the inflammatory reaction of regenerated cartilage tissue after in vivo implantation and promoting cartilage regeneration in vivo. Initiation date: Jan 2023 --> Apr 2023
|
